Zusammenfassung
GRUNDLAGEN: Antireflux-Chirurgie stellt eine gute Alternative zur medikamentösen Therapie der gastroösophagealen Refluxkrankheit (GERD) ohne Barrett-Ösophagus (BE) dar, bei denen sie die Entstehung eines BE verhindern soll. Diese Studie untersuchte die Entstehung von BE nach Antireflux-Chirurgie. METHODIK: Von 115 Personen ohne BE vor der Operation haben 12 (10,4 %) eine intestinale Metaplasie entwickelt und wurden mittels Endoskopie, Histologie und Funktionsdiagnostik untersucht. ERGEBNISSE: Die 12 Personen hatten durchschnittlich 5 Endoskopien mit Biopsien. Symptome bestanden bei 10 (83 %) Patienten 80 Monate nach der OP. Die Nachsorge betrug im Mittel 135 Monate. Vier Personen hatten keinen Reflux beim pH und Bilitec Monitoring; 8 Patienten hatten pathologischen Reflux. Es gab keinen Unterschied zwischen jenen mit normaler und pathologischer Refluxaktivität bezüglich Endoskopie, Histologie und Manometrie. Eine intestinale Metaplasie entstand in 58–90 Monaten ausgehend von cardiac oder oxyntocardiac mucosa. Vier Personen hatten eine Regression von intestinaler Metaplasie zu cardaic mucosa nach intensiver medikamentöser Therapie. SCHLUSSFOLGERUNGEN: Antireflux-Chirurgie kann die Entstehung eines BE in 10 % der Fälle nicht verhindern, wobei 1/3 der Personen pathologischen Reflux hatten. Mittels Histopathologie kann eine Progression von oxyntocardiac und cardaic mucosa zur intestinalen Metaplasie bzw. Dysplasie und Karzinom bzw. Regression vom BE zur cardiac und odyntocardiac mucosa monitiert und mit der Funktionsdiagnostik korreliert werden.
Summary
BACKGROUND: Surgical treatment in patients with gastroesophageal reflux disease (GERD) without Barrett's esophagus (BE) is an excellent alternative therapy to medical treatment, preventing the development of complications and the appearance of BE. PURPOSE: To determine the newly developed BE in a group of patients without BE prior to surgery, the patients were submitted to a late subjective and objective follow-up. METHODS: From 115 non-BE patients submitted to surgery and followed up for a long period, 12 (10.4%) developed intestinal metaplasia after operation. They were submitted to endoscopic, histologic, manometric and functional studies (24-h pH and Bilitec). RESULTS: The 12 patients had an average of 5 endoscopies after surgery with several biopsy samples. Symptoms of recurrent reflux were present in only 10 patients (83%) at a mean of 80 months after surgery. The mean follow-up was 135 months. Four patients showed the absence of pathologic reflux measured by 24-h pH and Bilitec monitoring, while 8 had the presence of abnormal acid reflux. There were no significant differences between endoscopic, histologic and functional studies comparing patients with the presence or absence of pathologic reflux. The time of appearance to intestinal metaplasia from cardiac or oxynto–Cardiac mucosa was 58–90 months. Four patients showed regression of intestinal metaplasia to cardiac mucosa after intensive medical treatment. CONCLUSIONS: Antireflux surgery in patients without BE does not prevent the late appearance of BE in near 10% of the cases, provided that a long-term follow-up is performed and several endoscopic and histologic evaluations are repeated. Near 2/3 of these patients showed the presence of acid reflux, while 1/3 showed no abnormal reflux. With this method of follow-up, metaplastic changes from cardiac to intestinal metaplasia and from intestinal metaplasia to low-grade dysplasia can be documented, as well as regression from intestinal metaplasia to cardiac mucosa.
References
Klinkenberg-Knoll EC, Festen HP, Jansen JB, Lamers CB, Nelis F, Snel P, Luckers A, Dekkers CP, Havu N, Meuwissen SG. Long term treatment with omeprazole for refractory reflux esophagitis. Efficacy and safety. Ann Inter Med 1994;121:161–7
Hallerback B, Unge P, Carling L, Edwin B, Glise H, Havu N, Lyrenas E, Lundberg K. Omeprazole or Ranitidine in long term treatment of reflux esophagitis. The Scandinavian Clinics for United Research Group. Gastroenterology 1994;107:1305–11
Vigneri S, Termini R, Leandro G, Badalamenti S, Pantalena M, Savarino V, Di Mario F, Battaglia G, Mela GS, Pilotto A, Plebani M, Davi G. A comparison of five maintenance therapies for reflux esophagitis. New Eng J Med 1995;333:1106–10
Campos GM, Peters JH, DeMeester TR, Oberg S, Crookes PF, Tan S, DeMeester SR, Hagen JA, Bremner CG. Multivariate analysis of factors predicting outcome after laparoscopic Nissen fundoplication. J Gastroent Surg 1999;3:292–300
Loustarinen M, Isolauri J, Laitinen J, Koskiven M, Keyrilainen O, Markkula H, Lelitinen E, Clusitalo A. Fate of Nissen fundoplication after 20 years. A clinical, endoscopical and functional analysis. Gut 1993;34:1015–20
Isolauri J, Loustarinen M, Viljakka M, et al. Long term comparison of antireflux surgery versus conservative therapy for reflux esophagitis. Ann Surg 1997;225:295–9
Loustarinen M. Nissen fundoplication for reflux esophagitis long term clinical and endoscopic results in 109 of 127 consecutive patients. Ann Surg 1993;217:329–37
Rantanen TK, Halme TV, Loustarinen ME, Karhumaki LM, Kononen EO, Isolauri JO. The long term results of open antireflux surgery in a community based health care center. Am J Gastroent 1999;94:1777–81
Johansson J, Johnsson F, Joelsson B, Floren CH, Walther M. Outcome 5 years after 360° fundoplication for gastroesophageal reflux disease. Brit J Surg 1993;80:46–9
Thor KBA, Silander T. A long term randomized prospective trial of the Nissen procedure versus a modified Toupet technique. Ann Surg 1989;210:719–24
Oberg S, Werner J, Johnsson F, Zilling TH, Van Holstein CS, Nilsson J, Walther B. Endoscopic surveillance of columnar lined esophagus. Frequency of intestinal metaplasia detection and impact of antireflux surgery. Ann Surg 2001;5:619–26
Csendes A, Braghetto I, Korn O. Late subjective and objective evaluation of antireflux surgery in patients with reflux esophagitis: analysis of 215 patients. Surgery 1989;374–82
Csendes A, Burdiles P, Korn O, Braghetto I, Huertas C, Rojas J. Late results of a randomized clinical trial comparing total fundoplication versus calibration of the cardia with posterior gastropexy. Brit J Surg 2000;87:289–97
Low DE, Anderson RP, Ives R, Ricciardelli E, Hill LD. Fifteen to twenty years results after the Hill antireflux operation. J Thorac Cardiovasc Surg 1989;48:444–50
Negre JB, Markkula HT, Keyrilainen O, Matikainen M. Nissen fundoplication. Results at 10 year follow up. Am J Surg 1983;146:635–8
DeMeester TR, Bonavina L, Albertucci M. Nissen fundoplication for gastroesophageal reflux disease. Ann Surg 1986;204:9–20
Stein HJ, Kauer WKJ, Feussner H, Siewert JR. Bile reflux in benign and malignant Barrett's esophagus. Effect of medical acid suppression and Nissen fundoplication. J Gastroent Surg 1998;2:333–41
DeMeester TR. Surgical therapy for Barrett's esophagus: prevention, protection and excision. Dis Esoph 2002;15:109–16
Theisen J, Oberg S. Surgical and medical therapies for GERD. Can we see into the future? Am J Gastroent 1998;93:1008–9
Gutschow CA, Schroder W, Prenzel K, Boelschweiler E, Romagnoli K, Collard JM, Holscher AH. Impact of antireflux surgery on Barrett's esophagus. Langenbeck's Arch Surg 2002;387:138–45
Wetscher GJ, Gadenstaetter M, Klinger PJ, Weiss H, Obrist P, Wykypiel H, Klaus A, Profanter C. Efficacy of medical therapy and antireflux surgery to prevent Barrett's esophagus in patients with gastroesophageal reflux. Ann Surg 2001;234: 627–32
Csendes A, Coronel M, Avendaño H. Endoscopic location of the squamous columnar junction in patients with gastroesophageal reflux. Rev Méd Chile 1996;124:1320–4
Csendes A, Burdiles P, Braghetto I, Smok G, Castro C, Korn O, Henríquez A. Dysplasia and adenocarcinoma after classic antireflux surgery in patients with Barrett's esophagus. Ann Surg 2002;235:178–85
Csendes A, Maluenda F, Braghetto I, Csendes A. Location of the lower oesophageal sphincter and the squamous columnar junction in 109 healthy controls and 778 patients with different degrees of endoscopic esophagitis. Gut 1993;34:21–7
Csendes A, Braghetto I, Burdiles P, Díaz JC, Maluenda F, Korn O. A new physiological approach for the surgical treatment of patients with Barrett's esophagus. Ann Surg 1997;226:123–33
Zaninotto G, DeMeester TR, Seenger W, Johansson KE, Cheung SC. The lower esophageal sphincter in health and disease. Am J Surg 1988;155:104–11
Csendes A, Burdiles P, Alvarez F, Maluenda F, Henríquez A, Quesada S, Csendes P. Manometric features of mechanically defective lower esophageal sphincter in control subjects and in patients with different degrees of gastroesophageal reflux. Dis Esoph 1996;9:290–1
DeMeester TR, Wang CI, Wernly JA, et al. Technique indications and clinical use of 24 hour intraesophageal pH monitoring. J Thorac Cardiovasc Surg 1980;79:656–670
Csendes A, Alvarez F, Burdiles P, Braghetto I. Magnitude of gastroesophageal reflux measured by 24-hour esophageal pH monitoring according to the degrees of endoscopic esophagitis. Rev Méd Chile 1994;122:59–67
Csendes A, Braghetto I, Burdiles P, Puente J, Korn O, Díaz JC. Long term results of classic antireflux surgery in 152 patients with Barrett's esophagus: clinical, radiologic, endoscopic, manometric and acid reflux analysis before and late after operation. Surgery 1998;126:645–57
Oberg S, Peters JH, DeMeester TR. Inflammation and specialized intestinal metaplasia of cardiac mucosa is a manifestation of gastroesophageal reflux disease. Ann Surg 1997;226:522–30
Csendes A, Smok G, Burdiles P, Sagastume H, Rojas J, Puente G, Quezada F, Korn O. "Carditis": an objective histological marker for pathologic gastroesophageal reflux disease. Dis Esoph 1998;11:101–5
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Csendes, A., Smok, G., Burdiles, P. et al. Barrett's esophagus can develop after antireflux surgery. Eur Surg 40, 245–252 (2008). https://doi.org/10.1007/s10353-008-0426-9
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s10353-008-0426-9